Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Resverlogix Corp T.RVX

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  RVXCF

Resverlogix Corp is a clinical stage cardiovascular company. It is engaged in developing small molecules that selectively inhibit Bromodomain and ExtraTerminal domain (BET) proteins, a new and emerging target for high risk vascular diseases.
Price: $2.40 | Change: +$0.20 | %Change: +9.09%
Volume: 155,228 | Day High/Low: 2.52/2.23 | 52 Week High/Low: 3.13/0.405
View modes: 
5 stars

Great to See

......that we're holding on sustained volume..would guess that the shorts are scrambling today :) nice overdue bump today to close out the week on a high note!  rate and reply
5 stars

RE:RE:In talking with Sarh this morning

Hello Prince. When I see you posting I think of the prince connection from Dilbert of "Phil the Prince of inadequate light". I will respond to your question "ask is crestor a freerider or positive...read more
1 star

RE:In talking with Sarh this morning

fuzzythinking, ROTFLMAO..i call BS to your post...so a pumper like you speaks to Sarah (whoever she is and your pumpers SOP of constantly bombarding RVX is a huge tell) and she makes statements to you...read more
3 stars

RE:In talking with Sarh this morning

That's a real plus "the actual start do dosing". Certainly not case in past trials. (Interesting early jump,up,to $2.50 today!)  rate and reply
3.5 stars

RE:In talking with Sarh this morning

Wow good info there Fuzz. Thanks for sharing. Enjoy the weekend everyone. Looks like a nice upward move so far this morning in the pps to help in that regards.  rate and reply
4 stars

In talking with Sarh this morning

The trial is still expected to start second half of 2015 - nothing has changed there regardless of what some may spout. Another interesting tid bit is when some companies announce the start of their...read more
1 star

RE:RE:NEW BLOG POST

bear, given that this is the premise of BoM and their current thesis (maybe this time they will be right) i would be suspicious of any other focus...i wonder how ema and fda meetings went..again...read more
5 stars

RE:NEW BLOG POST

Looks like they are really emphasizing the diabetes and kidney disease therapeutic potential right now. At the bottom of the blog post, they state: "Resverlogix will be attending two upcoming...read more
5 stars

NEW BLOG POST

Y We have published a new blog post on our website. Resverlogix: Our Interest in Chronic Kidney Disease Diabetes Mellitus (DM) is known to be the underlying cause for many long term health...read more
1 star

RE:Zenith?

bayou, here is my non-rose coloured answer...it was a stoopid silly and strategically inane gift, i heard of it owned RVX long enough to get the freebies and then bailed on RVX...recently bought back...read more
5 stars

RE:Zenith?

bayou..a bit more info for you; However zenith shares are owned by shareholders that held shares in RVX prior to the spin-off. Shareholders after spin-off do not own Zenith shares. IMO...some may...read more
0 stars

RE:Zenith?

Bayou, take a look at the RVX NR RE THIS SPIN OUT OF ZENITH:        http://www.resverlogix.com/media/press-release.html?id=484  rate and reply
1 star

Zenith?

Can anyone tell me what if any interest RVX has in Zenith in the way of equity? I emailed the co. 8 days ago asking this question and haven't had the courtesy of a reply yet.  Was the spinoff a "gift"...read more
5 stars

RE:RE:Amgen Dumps AstraZeneca

Hello toinv....there is no question that we need Phase 3 underway in a very bad way to prove the full benefits of RVX-208, once and for all, come hell or high water.   You always bring great...read more
5 stars

RE:Amgen Dumps AstraZeneca

Hi GV. That is interesting because they dumped the development because of restrictions required on the label and thus a restricted population market. With rvx-208 the BETonMACE target market is...read more
5 stars

Discovery on Target Conference

Sept 23. Last speaker. http://www.discoveryontarget.com/epigenetic-readers/ 10:55 BET Proteins; Selective and Pan-Inhibition for Treating Human Diseases Norman C.W. Wong, M.D., FRCP, CSO & Co-Founder,...read more
5 stars

Discovery on Target Conference

Sept 23. Last speaker. http://www.discoveryontarget.com/epigenetic-readers/ 10:55 BET Proteins; Selective and Pan-Inhibition for Treating Human Diseases Norman C.W. Wong, M.D., FRCP, CSO & Co-Founder,...read more
5 stars

Three conferences over one week

Resverlogix is spending the week on the other side of the pond at these three conferences according to the events page. They had two poster presentations at ISA on May 26th but Resverlogix didn't...read more
0 stars

BIG PHARMA- DRUG PRICES

May 27, 2015  By Karl Thiel for BioSpace.com  For decades, pharma and biotech companies have been vilified for excessive prices. The dance of accusation and justification has become yawn-worthy to...read more
0 stars

PCSK9 PRICE WAR PREP.

1. The Gilead effect: PCSK9 rivals Amgen, Sanofi/Regeneron prep for a price war   By John Carroll  Comment | Forward | Twitter | Facebook | LinkedIn ...read more